CAM
FATE icon

ClariVest Asset Management’s Fate Therapeutics FATE Stock Holding History

ClariVest Asset Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-11,834
Closed -$265K – 706
2022
Q3 		$265K Sell
11,834
-33
-0.3% -$953 0.01% 416
2022
Q2 		$294K Hold
11,867
– – 0.01% 430
2022
Q1 		$460K Hold
11,867
– – 0.02% 401
2021
Q4 		$695K Sell
11,867
-721
-6% -$40.9K 0.02% 384
2021
Q3 		$746K Sell
12,588
-458
-4% -$35.9K 0.02% 366
2021
Q2 		$1.13M Buy
13,046
+30
+0.2% +$2.42K 0.04% 276
2021
Q1 		$1.07M Sell
13,016
-800
-6% -$76.7K 0.04% 277
2020
Q4 		$1.26M Sell
13,816
-18,751
-58% -$1.16M 0.04% 250
2020
Q3 		$1.3M Sell
32,567
-1,476
-4% -$51.5K 0.04% 276
2020
Q2 		$1.17M Buy
+34,043
New +$1.01M 0.03% 304

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClariVest Asset Management's FATE Position: Q4 2022 in Review

ClariVest Asset Management sold out of Fate Therapeutics (FATE) in Q4 2022, closing a stake of 11,834 shares — an estimated $265K sold.

ClariVest Asset Management first reported a position in FATE in Q2 2020 and held it in 10 quarters. The position peaked at $1.3M in Q3 2020. 227 funds tracked by Wall St. Rank hold FATE as of Q4 2022.

  • ClariVest Asset Management reported no remaining Fate Therapeutics position as of Q4 2022 after selling out during the quarter.
  • ClariVest Asset Management sold 11,834 Fate Therapeutics shares in Q4 2022, an estimated $265K.
  • ClariVest Asset Management first reported a position in Fate Therapeutics in Q2 2020 and held it in 10 quarters.
  • ClariVest Asset Management's Fate Therapeutics position peaked at $1.3M in Q3 2020.
  • 227 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2022.

Based on ClariVest Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.